BFM
CTSO icon

Boothbay Fund Management’s Cytosorbents Corp CTSO Stock Holding History

Boothbay Fund Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,944
Closed -$54K – 884
2019
Q4 		$54K Buy
+13,944
New +$60.8K ﹤0.01% 803

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Boothbay Fund Management's CTSO Position: Q1 2020 in Review

Boothbay Fund Management sold out of Cytosorbents Corp (CTSO) in Q1 2020, closing a stake of 13,944 shares — an estimated $54K sold.

Boothbay Fund Management first reported a position in CTSO in Q4 2019 and held it in 1 quarter. The position peaked at $54K in Q4 2019. 82 funds tracked by Wall St. Rank hold CTSO as of Q1 2020.

  • Boothbay Fund Management reported no remaining Cytosorbents Corp position as of Q1 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 13,944 Cytosorbents Corp shares in Q1 2020, an estimated $54K.
  • Boothbay Fund Management first reported a position in Cytosorbents Corp in Q4 2019 and held it in 1 quarter.
  • Boothbay Fund Management's Cytosorbents Corp position peaked at $54K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2020.

Based on Boothbay Fund Management's 13F filing for Q1 2020, filed 15 May 2020.